Quratis Inc. (KOSDAQ:348080)

South Korea flag South Korea · Delayed Price · Currency is KRW
848.00
-18.00 (-2.08%)
At close: Apr 28, 2026
-18.38%
Market Cap 89.51B
Revenue (ttm) 2.46B
Net Income (ttm) -29.67B
Shares Out 105.56M
EPS (ttm) -412.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 468,555
Average Volume 536,526
Open 866.00
Previous Close 866.00
Day's Range 805.00 - 874.00
52-Week Range 633.00 - 2,095.00
Beta -0.19
RSI 39.13
Earnings Date n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348080
Full Company Profile

Financial Performance

In 2025, Quratis's revenue was 2.46 billion, an increase of 557.29% compared to the previous year's 373.80 million. Losses were -29.67 billion, 13.0% more than in 2024.

Financial Statements

News

There is no news available yet.